CEFNUS-200 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
CEFNUS-200 LB
Cefixime 200mg With Lactic Acid Becillus Dispersible Tablet
CEFNUS-200 is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
CEFNUS-200 LB features Cefixime 200mg With Lactic Acid Becillus Dispersible Tablet prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Administered in our secondary care for CEFNUS-200
CEFNUS-200 has been administered in our secondary care clinic for acute indications, providing rapid onset of relief with outstanding tolerability across diverse age brackets. Moisture barrier protection is noticeably superior, preventing tablet softening during monsoon transit. One of our fastest-moving items with steady prescription flow from local healthcare providers.
Questions Regarding CEFNUS-200 LB
What is the therapeutic indication and composition of CEFNUS-200?
CEFNUS-200 contains Cefixime 200mg With Lactic Acid Becillus Dispersible Tablet indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for CEFNUS-200?
CEFNUS-200 is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for CEFNUS-200?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for CEFNUS-200 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
CEFNUS-200 is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
